Oxalate metabolism in end-stage renal disease: The effect of ascorbic acid and pyridoxine

Nephrology Dialysis Transplantation

Volumn 3, Issue 1, 1988, Pages 28-32

  Morgan, S H ^a   Maher, E R ^b   Purkiss, P ^a   Watts, R W E ^a   Curtis, J R ^b  

^a MRC Clinical Research Centre   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Ascorbic acid; Chronic ambulatory peritoneal dialysis; Haemodialysis; Oxalate; Pyridoxine; Renal failure

Indexed keywords

ASCORBIC ACID; OXALIC ACID; PYRIDOXINE;

ADULT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HEMODIALYSIS; HUMAN;

ADULT; AGED; ASCORBIC ACID; FEMALE; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGE; OXALATES; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PYRIDOXINE; RENAL DIALYSIS;

EID: 0023889912     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a091615     Document Type: Article

References (42)

1. Zarembski PMA. Hodginson A. Parsons FM. Elevation of the concentration of plasma oxalic acid in renal failure. Nature 1966; 212: 511-512
2. Morgan SH, Purkiss P, Watts RWE, Mansell MA. Oxalate dynamics in chronic renal failure: Comparison with normal subjects and patients with primary hyperoxaluria. Nephron 1987; 46:253-257
3. Fayemi OA. Ali M. Braun EV. Oxalosis in hemodialysis patients. Arch Pathol Lab Med 1979; 103: 58-62
4. Thompson CS. Weinman EJ. The significance of oxalate in renal failure. Am J Kidney Dis 1984; 4:97-99
5. Milwall A. Oreopoulos DC Hyperoxaluria and hyperoxalemia: One more concern for the nephrologist. Int J Artif Organs 1985; 8: 71-74
6. Atkins GL. Dean BM, Griffin WJ, Watts RWE. Quantitative aspects of ascorbic acid metabolism in man. J Biol Chem 1964; 239:2975-2980
7. Lamden MP. Chrystowski GA. Urinary oxalate excretion by man, following ascorbic acid ingestion. Proc Soc Exp Biol Med 1954; 85: 190-192
8. Hatch M. Mulgren S. Bourke E et al. Effect of megadoses of ascorbic acid on serum and urine oxalate. European Urol 1980; 6:166-189
9. Balcke P, Schmidt P, Zazgornik J, Kopsa H, Haubenstock A. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med 1984; 101: 344-345
10. Smith LH. Risk of oxalate stones from large doses of vitamin C. N. Eng J Med 1978; 298: 856
11. Dobblestein H. Korner WF, Hempel W, Grossewill H, Edel HH. Vitamin B6 deficiency in uremia and its implications for the depression of the immune response. Kidney Int 1974; 5: 233-239
12. Watts RWE. Veall N, Purkiss P, Mansell MA. Haywood EF. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria). Clin Sci 1985; 69: 87-90
13. Danpure CJ, Jennings PR. Peroxisomal alanine-.glyoxylate aminotransferase deficiency in primary hyproxaluria type I. FEBS Lett 1986; 201:20-24
14. Danpure CJ, Jennings PR, Watts RWE. Enzymological diagnosis of primary hyperoxaluria type I by measurement of hepatic alanine: Glyoxylate aminotransferase activity. Lancet 1987: 1:289-291
15. Kasidas GP, Rose GA. Measurement of plasma oxalate in healthy subjects and in patients with chronic renal failure using immobilised oxalate oxidase. Clin Chim Ada 1986; 154:49-58
16. Watts RWE, Veall N, Purkiss P. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci 1984; 66: 591-597
17. Constable AR, Joekes AM, Kasidas GP et al. Plasma level and renal clearance of oxalate in normal subjects and in patients with primary hyperoxaluria or chronic renal failure or both. Clin Sci 1979; 56: 299-304
18. Balcke P. Schmidt P. Zazgornik J, Kopsa H, Deutsch E. Secondary oxalosis on chronic renal insufficiency. N Eng J Med 1980; 303:994
19. Watts RWE, Veall N, Purkiss P. Sequential studies of oxalate dynamics in primary hyperoxaluria. Clin Sci 1983; 65:627-633
20. Lewis R, Lowenstam H, Rossman G. Oxalate nephrosis and crystalline myocarditis. Arch Pathol 1974; 98: 149-155
21. Salyer WR, Hutchins GM. Cardiac lesions in secondary oxalosis. Arch Intern Med 1974; 134: 250-252
22. Wu G. Cardiovascular deaths amongst CAPD patients. Peril Dial Bull 1983 [Suppl]; 3: 251
23. Ishida K, Yamanaka N. Oxalosis in chronic renal failure or chronic dialysis or both. Nippon Hinyokika Gakkai Zasshi 1980; 71: 1423-1431
24. O’Callaghan JW, Arbuckle SM, Crasnell PW, Boyle PP, Searle JN, Smythe WR. Rapid progression of oxalosis induced cardio-myopathy despite adequate haemodialysis. Miner Electrolyte Metab 1984; 10:48-51
25. Op de Hoek CT, Diderich PNM, Gratama S, Weiss v Hofwegen EJM. Oxalosis in chronic renal failure. Proc Eur Dial Transplant Assoc 1980; 17: 30-35
26. Hoffman GS, Shumacher HR, Paul H et al. Calcium oxalate micro-crystalline associated arthritis in end stage renal disease. Ann Intern Med 1982; 97:36-42
27. Oreopoulos DG, Silverberg S. Calcium oxalate urinary tract stones in patients on maintenance dialysis. N Eng J Med 1974; 290; 1438-1439
28. Carals A, Lloveras J, Andrev J, Brulies A et al. Urinary calculi in chronic dialysis patients. Lancet 1979; 2: 1024-1025
29. Koga W, Nomura G, Yamagata Y, Koga T. Ureteric pain in patients with chronic renal failure on haemodialysis. Nephron 1982; 31:55-58
30. Oren A, Husdan H, Cheng P et al. Calcium oxalate kidney stones in patients on chronic ambulatory peritoneal dialysis. Kidney Int 1984; 25: 534-538
31. Boer P, v Leersum L, Hene RS, Mees EJ. Plasma oxalate concentration in chronic renal disease. Am J Kidney Dis 1984; 4: 118-122
32. Ramsay AG. Reed RG. Oxalate removal by hemodialysis in end stage renal disease. Am J Kidney Dis 1984; 4: 123-127
33. Yamuachi A, Fuji M, Shirai D et al. Plasma concentration and peritoneal clearance of oxalate in patients on CAPD. Clin Nephrol 1986:25: 181 185
34. Sullivan JF. Eisenstein AB. Ascorbic acid depletion in patients undergoing chronic hemodialysis. Am J Clin Nutr 1944; 23: 1339-1346
35. Bradley DW, Maynard JE, Webster H. Plasma and whole blood concentration of ascorbic acid in patients undergoing long term haemodialysis. Am J Clin Pathol 1973; 59: 145-147
36. Pru C. Eaton J. Kjellstrand C. Vitamin C intoxication in chronic haemodialysis patients. Nephron 1985; 39: 112-116
37. Gershoff SN. Vitamin B6 and oxalate metabolism. Vitam Horm 1964; 22:581-589
38. Ribaya-Mercado JD, Gershoff SN. Factors affecting endogenous oxalate synthesis and its excretion in feces and urine in rats. J Nutr 1982; 112:2161-2169
39. Stone WJ, Warnock LG, Wagner C. Vitamin B6 deficiency in uremia. Am J Clin Nutr 1975; 28:950-957
40. Worcester EM, Nakagana Y, Bushinsky A, Coe FL. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest 1986; 77:888-896
41. Barsotti G, Cristofano C, Morelli E, Meola M, Luppetti S, Giovanetti S. Serum oxalic acid in uraemia: The effect of low protein diet supplemented by essential amino acids and ketoanalogues. Nephron 1984; 38: 54-56
42. Martin X, Werness PG, Bergers JH. Smith LH. Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urology 1984; 132:786-788